CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The U.S. government on Wednesday refused to override patents on the anti-HIV drug Norvir, effectively allowing a quintupling of the price to stand despite consumer groups' accusations of price gouging. Patient groups and some members of Congress had pushed the National Institutes of Health to take the unprecedented action, arguing it was warranted under a special law because Norvir's discovery was partially funded by taxpayer dollars. But the NIH decided that such an extraordinary step could have overly broad effects on the pharmaceutical market and would exceed that law's intent. "The issue of drug pricing has global implications and, thus, is appropriately left for Congress to address legislatively," concluded Elias Zerhouni, NIH director. Abbott Laboratories raised the price of a single dose of the eight-year-old Norvir to $8.57 a day from $1.71 late last year. The impact reached far beyond that one drug: Low doses of Norvir are used to boost the effects of other anti-HIV medicines, meaning patients taking a wide array of antiretroviral drug cocktails faced substantially higher bills. Consumer advocates decried that the increased price applied only to the United States, leaving Norvir five to 10 times cheaper in other countries. They also called it anticompetitive because it applied only when Norvir is added to other companies' anti-HIV medicines, not Abbott's own Kaletra, a medicine with Norvir built into the pill. The price hike came amid already vigorous debate about why Americans pay much more for prescription drugs than do patients in such countries as Canada and the United Kingdom. Citing a $3.5 million NIH grant that helped lead to Norvir's discovery, the consumer group Essential Inventions petitioned the government to grant licenses for other companies to make the medicine too. Their aim: driving the drug's price down. The 24-year-old Bayh-Dole Act gives the NIH the right to claim patents of inventions partly funded by the government--if companies don't bring the innovations to market in ways that "achieve practical application." "It's a horrible decision," Robert Weissman, Essential Inventions general counsel said of Wednesday's decision. The NIH ruling means that drugmakers "can put government-funded inventions on the market at any price whatsoever without facing the possibility of a margin." The decision suggests "it doesn't matter what drugmakers charge for a taxpayer-subsidized drug, as long as they continue to sell it," complained Rep. Sherrod Brown (D-Ohio). Brown and Weissman pledged to appeal to Health and Human Services secretary Tommy Thompson to overrule the NIH decision. A Thompson spokesman didn't immediately return a call for comment. Abbott welcomed the decision. The company maintains that the higher price is necessary to counter falling sales as Norvir's use has shifted from a primary agent to a low-dose booster. Sales fell to $100 million last year from a high of $250 million in 1998. Norvir sales have totaled more than $1 billion since its introduction. The company also says the NIH grant represented a tiny portion of the roughly $300 million it ultimately spent developing Norvir, expenses it needs to recoup to invest in new research. "This is good news for patients who will continue to benefit from both current and future innovations that result from the advent of the Bayh-Dole Act," said Melissa Brotz, Abbott spokeswoman. The NIH did say its sister organization, the Federal Trade Commission, would be the proper agency to address allegations that Norvir's price is anticompetitive. Brotz said the FTC recently notified the company that the agency had no plans to investigate. (AP)
From our Sponsors
Most Popular
31 Period Films of Lesbians and Bi Women in Love That Will Take You Back
December 09 2024 1:00 PM
18 of the most batsh*t things N.C. Republican governor candidate Mark Robinson has said
October 30 2024 11:06 AM
True
After 20 years, and after tonight, Obama will no longer be the Democrats' top star
August 20 2024 12:28 PM
Trump ally Laura Loomer goes after Lindsey Graham: ‘We all know you’re gay’
September 13 2024 2:28 PM
These 15 major companies caved to the far right and stopped DEI programs
January 24 2025 1:11 PM
True
Melania Trump cashed six-figure check to speak to gay Republicans at Mar-a-Lago
August 16 2024 5:57 PM
Latest Stories
Dad's heartwarming reaction to his son coming out as gay goes viral 8 years later
February 11 2025 12:55 PM
Trump taps gay MAGA loyalist Ric Grenell as interim head of Kennedy Center
February 11 2025 11:52 AM
Google Calendar removes Pride Month and Black History Month shortly after dropping DEI
February 11 2025 11:20 AM
Trump Pentagon chief Pete Hegseth enacts harshest anti-trans military policies yet
February 11 2025 9:57 AM
Protecting the rights of LGBTQ+ families in the second Trump presidency
February 11 2025 7:00 AM
Three convicted in murders of gay men in New York City
February 10 2025 7:59 PM
Trump's Education Department investigates schools for trans inclusion in sports
February 10 2025 5:53 PM
GLAAD responds as WWE chooses not to renew lesbian wrestler Sonya Deville’s contract
February 10 2025 3:34 PM
Rally for transgender youth overtakes New York City's Union Square, in photos
February 10 2025 2:35 PM
Anti-LGBTQ+ policies harm the health of not only LGBTQ+ people, but all Americans
February 10 2025 1:58 PM